News
Topline pivotal Phase 3 firmonertinib data. ArriVent anticipates having topline firmonertinib monotherapy data from the event-driven global pivotal FURVENT Phase 3 (NCT05607550) study in 2025 and ...
Funding will enable company to expand research capacity and scale up unique genome editing technology designed to treat ...
A review of all the action from Round 4 of the 2025 rebel VFLW season. DAREBIN FALCONS 0.2 1.3 1.6 3.8 (26) COLLINGWOOD 1.2 2.3 3.3 3.5 (23) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback